Proteonomix (PROT) Senior Management Meets With Investment Community
(firmenpresse) - MOUNTAINSIDE, NJ -- (Marketwire) -- 09/06/11 -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that Michael Cohen, Chief Executive Officer of Proteonomix and Ian McNiece, the Company's Chief Scientific Officer met today with the team at , the Company's Investment Banker, and . They updated them on the development of the Company's technology and the Company's technical position in several different areas of research and development.
Proteonomix CEO Michael Cohen stated, "Proteonomix is on the cusp of entering a new phase of its development and well on its way to becoming a significant force in the biotech world. We are at present not covered by any analysts in the industry and hope to gain such coverage in the near future. We anticipate that such coverage will assist the investing public is recognizing the achievements of Proteonomix both in bringing our Proteoderm anti-aging skin care line to the point where marketing can commence, as well as moving ever closer to commencement of clinical trials for our ."
and a member of the Board, noted, "Our Company has made extraordinary progress on a limited budget both in the realm of product development and in its working relationship with the academic community. Our anticipated clinical trial moves ever closer to fruition and the Company's patent position is remarkable for such an early stage company."
The Company will be filing a version of the PowerPoint presentation made today, along with the Form 8-K filing for this press release.
About Proteonomix, Inc.: Proteonomix is a biotechnology company focused on developing therapeutics based upon use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI, The Sperm Bank of New York and THOR BioPharma. Proteoderm, Inc. is wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit , , and .
Forward-looking statements: Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2011 - 16:20 Uhr
Sprache: Deutsch
News-ID 63088
Anzahl Zeichen: 0
contact information:
Town:
MOUNTAINSIDE, NJ
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Proteonomix (PROT) Senior Management Meets With Investment Community"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteonomix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
